Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01404585 | Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis | PHASE2 | COMPLETED | 123 | — | — | Sep 1, 2011 | Feb 1, 2013 | Oct 12, 2015 | 29 | United States, Argentina +5 |
| Arm | Type | Description |
|---|---|---|
| Arm 1: Placebo | PLACEBO_COMPARATOR | - |
| Arm 2: BMS-817399 (200 mg) | EXPERIMENTAL | - |
| Arm 3: BMS-817399 (400 mg) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Tablets, Oral, 0 mg, twice daily, 12 weeks |
| BMS-817399 | DRUG | Tablets, Oral, 200 mg, twice daily, 12 weeks |
Inclusion Criteria: * Male or female subjects, 18 years of age or older, with rheumatoid arthritis (RA) for at least 6 months prior to screening * Subjects must have a tender joint count of at least 6 (28 joint count), swollen joint count of at least 6 (28 joint count) at screening. All subjects mu...